Torisel

Phase 2

PFIZER (PFE)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Adenocarcinoma

View Full Landscape

Drug Information

Target Indication

Adenocarcinoma

Clinical Trial

NCT00106353

Last updated: 1/17/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA11/19/2007

Torisel

Renal-cell carcinoma Torisel is indicated for the first-line treatment of adult patients with advanced renal-cell carcinoma (RCC) who have at least three of six prognostic risk factors. Mantle-cell lymphoma Torisel is indicated for the treatment of adult patients with relapsed and / or refractory mantle-cell lymphoma (MCL).

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

PFE

PFIZER

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

FSME-IMMUN NEW 0.25 mlPhase 3

Tick-borne Encephalitis

AvelumabPhase 3

Urothelial Cancer